Dynavax Technologies

Last Updated:

Q3 '20


quotes and stock data delayed 15 minutes



Burn Rate (Qtr)


Company Profile

Dynavax is a fully-integrated biopharmaceutical company focused on leveraging the power of the body’s innate and adaptive immune responses through Toll-like Receptor (TLR) stimulation. Dynavax develops, and commercializes novel vaccines.

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date


Hepatitis B Vaccine

Quarterly Sales (Approved)

February 24, 2021 (Est)

SARS-CoV-2 Inactivated Vaccine (with Sinovac)

COVID-19 Vaccine

Phase 3 Readout


COVID-19 S-Trimer (with Clover Biopharmaceuticals)

COVID-19 Vaccine

Phase 1 (Preliminary safety and immunogenicity results)

Q4 2020 (Est)

COVID-19 Vaccine (with Medicago)

COVID-19 Vaccine

Phase 1 (Preliminary safety and immunogenicity results)

Q4 2020 (Est)

Vaccine Candidate (with Valneva)

COVID-19 Vaccine



Vaccine Candidate (with Coalition for Epidemic Preparedness Innovations (CEPI) and Queensland)

COVID-19 Vaccine



Recent Posts

See what the community is saying - click to see full post

DVAX - Dynavax Announces Third Quarter 2020 Financial Results

DVAX - Dynavax to Report Q3 2020 Financial Results and Host Conference Call on November 5, 2020

DNVAX’s Hepatitis B Vaccine, Heplisav-B, Q2 2020 Sales Plummeted

DVAX - Presenting Preliminary Phase 1 COVID-19 Vaccine in Sept & Oct 2020

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon